8-K: Avadel Ordered to Pay 3.85% Royalty on LUMRYZ Sales

Avadel Pharmaceuticals' subsidiary, Avadel CNS, has been ordered by a U.S. District Court to pay Jazz Pharmaceuticals an ongoing 3.85% royalty on LUMRYZ sales until February 2036 due to patent infringement.

Summary

• A U.S. District Court issued an order on September 15, 2025, requiring Avadel CNS Pharmaceuticals, LLC, a wholly owned subsidiary of Avadel Pharmaceuticals plc, to pay an ongoing royalty to Jazz Pharmaceuticals, Inc.
• The royalty rate is set at 3.85% on sales of LUMRYZ.
• This payment is mandated for infringement of Jazz's U.S. Patent No. 11,147,782.
• The royalty obligation will continue through the expiration of the 782 Patent on February 18, 2036.
• Avadel disagrees with the underlying jury decision regarding the validity of the 782 Patent and plans to continue contesting that decision and any related royalty obligation.
• Avadel has and will continue to accrue the royalty and recognize the corresponding liability on its balance sheet.

Sentiment

Score: 3

Explanation: The imposition of a long-term royalty payment on a key product is a negative financial development, reducing future profitability. While Avadel plans to contest, the immediate impact is a confirmed liability.

Negatives

• A court order requires Avadel CNS to pay a 3.85% ongoing royalty on LUMRYZ sales to Jazz Pharmaceuticals, representing a new, long-term financial obligation.
• The royalty obligation extends until February 18, 2036, which will impact the profitability of LUMRYZ for over a decade.
• Avadel must accrue the royalty and recognize the liability on its balance sheet, which will negatively affect its financial statements.

Risks

• Uncertainty and potential financial impact associated with contesting the jury decision regarding the validity of the 782 Patent and the related royalty obligation.
• General risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings, which could cause actual results to differ materially from expectations.

Future Outlook

Avadel plans to continue contesting the jury decision regarding the validity of the 782 Patent and any related royalty obligation. The company expects to continue accruing the royalty and recognizing the liability on its balance sheet.

Management Comments

• Avadel disagrees with the underlying jury decision regarding the validity of the 782 Patent and plans to continue contesting that decision and any related royalty obligation.
• Avadel has and will continue to accrue the royalty as well as recognize liability for same on the balance sheet.

Industry Context

Patent litigation is a common and significant risk within the pharmaceutical industry, particularly for innovative drugs. This court order impacts the profitability and competitive landscape for LUMRYZ, a key product for Avadel, by imposing a long-term royalty payment to a competitor. Such outcomes can influence investor perception of a company's intellectual property strength and future earnings potential.

Legal Proceedings

• Ongoing lawsuit initiated by Jazz Pharmaceuticals, Inc. against Avadel CNS Pharmaceuticals, LLC in the U.S. District Court for the District of Delaware regarding alleged infringement of Jazz's U.S. Patent No. 11,147,782 by LUMRYZ.
• The Court issued an opinion and order on September 15, 2025, requiring Avadel CNS to pay a future ongoing royalty of 3.85% on LUMRYZ sales to Jazz through February 18, 2036.

Stakeholder Impact

• Shareholders: Potential reduction in future earnings and profitability for LUMRYZ, impacting share value. Increased legal costs due to ongoing contestation.
• Customers: No direct immediate impact on product availability or pricing mentioned.

Next Steps

• Avadel plans to continue contesting the jury decision regarding the validity of the 782 Patent.
• Avadel will continue to contest any related royalty obligation.
• Avadel will continue to accrue the royalty and recognize liability on its balance sheet.

Key Dates

Recommendation

The confirmed 3.85% ongoing royalty on LUMRYZ sales until 2036 represents a material, long-term reduction in the product's profitability. While Avadel intends to contest the decision, the immediate financial impact is negative, introducing uncertainty and a drag on future earnings. Investors should monitor the outcome of Avadel's appeal and its impact on the company's financial projections.

Keywords

Avadel Pharmaceuticals, Jazz Pharmaceuticals, LUMRYZ, patent infringement, royalty, litigation, pharmaceuticals, intellectual property, 8-K